2. Cancer
  3. Cancer Immunotherapy

Cancer Immunotherapy

Cancer immunotherapy (CIT) is a type of biological therapy, aiming to improve anti-tumor immune responses with fewer off-target effects than chemotherapy. Several types of immunotherapy include: oncolytic virus therapies, cancer vaccines, cytokine therapies, adoptive cell transfer (ACT), and immune checkpoint inhibitors (ICIs). In particular, ICIs and ACT have obtained immense clinical response, but their efficacy varies from person to person. Immune cells can be harnessed to eliminate tumor cells, such as T cells, B cells, NK cells, and myeloid cells. T cells have potent tumor-killing capability, therefore, a plethora of cancer immunotherapy research have focused on inducing T-cell-mediated anti-tumor responses. CTLA-4 and PD-1 are found on the cell surface of T cells as co-inhibitory receptors. The breakthrough in cancer immunotherapy results from the identification and subsequent targeting of checkpoint mechanisms in T cells with monoclonal antibodies against CTLA-4 and programmed death-ligand 1/programmed death-1 (PD-L1/PD-1).

Several types of cancers (e.g., melanoma, mismatch repair-deficient cancers, bladder cancer, and non-small cell lung cancer) have achieved significant clinical responses in T-cell checkpoint blockade therapies. However, single-mode immunotherapy faces challenges such as low immune response, low tumor infiltration, and complex immunosuppressive tumor microenvironment. Recently, combined therapies based on tumor immunity have received extensive attention in the research of enhancing tumor cells immunogenicity and inhibiting their growth. For example, anti CTLA-4 and PD-1, immune checkpoint blockade (ICB) combined with chemotherapy, anti-angiogenic drugs and kinase inhibitors.

Productos relacionados con Cancer Immunotherapy (13050):

Cat. No. Nombre del producto No. CAS Pureza Estructura química
  • HY-179506
    p53 Activator 16
    P53 Activator 16 (Compound JC16) is a p53 activator. P53 Activator 16 exhibits selective cytotoxicity and pro-apoptotic (apoptosis) activity towards p53-Y220C mutant cancer cells, while having little effect on wild-type or P53-deficient cells. P53 Activator 16 induces the conformational transition of cell p53-Y220C from the mutant form to the wild-type form, accompanied by the transcriptional activation of p53 target genes, without increasing the overall level of p53 protein. P53 Activator 16 can be used for the study of p53 mutant cancers.
    p53 Activator 16
  • HY-P1876A
    NLS (PKKKRKV) TFA
    NLS (PKKKRKV) TFA is the TFA form of NLS (PKKKRKV) (HY-P1876). NLS (PKKKRKV) is a nuclear localization signal (NLS) derived from the simian virus 40 large tumor antigen (SV40 large T antigen), that mediates binding of the karyophilic protein to importin α. NLS (PKKKRKV) can function as a method to enhance nuclear entry in the field of gene transfer research.
    NLS (PKKKRKV) TFA
  • HY-P992010
    ALMB-0168
    ALMB-0168 is a Cx43 hemichannel agonist monoclonal antibody. ALMB-0168 activates Cx43 hemichannels to inhibit the growth and migration of osteosarcoma. ALMB-0168 is applicable to relevant research on osteosarcoma.
    ALMB-0168
  • HY-P3139A
    TPP-1 TFA
    TPP-1 TFA is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 TFA binds specifically to PD-L1 with a high affinity (KD=95 nM). TPP-1 TFA inhibits human tumor growth in vivo via reactivating T-cell function.
    TPP-1 TFA
  • HY-W740773
    Betamethasone-d10 Dipropionate
    Betamethasone-d10 Dipropionate is the deuterium labeled Betamethasone dipropionate (HY-13571). Betamethasone dipropionate is a glucocorticoid steroid with anti-inflammatory and immunosuppressive abilities.
    Betamethasone-d<sub>10</sub> Dipropionate
  • HY-10353AS1
    Raltegravir-13C,d3 potassium
    Raltegravir-13C,d3 potassium is 13C labeled Raltegravir potassium (HY-10353A). Raltegravir (MK 0518) potassium is a potent integrase (IN) inhibitor, used to treat HIV infection.
    Raltegravir-<sup>13</sup>C,d<sub>3</sub> potassium
  • HY-P991339
    ZL-1101
    ZL-1101 is a human monoclonal antibody (mAb) targeting TNFRSF4/OX40/CD134.
    ZL-1101
  • HY-W767399
    8-Bromo-2'-deoxyguanosine-13C,15N2
    8-Bromo-2'-deoxyguanosine-13C,15N2 is the 13C- and 15N-labeled 8-Bromo-2'-deoxyguanosine (HY-W011168). 8-Bromo-2'-deoxyguanosine is an inflammation-related DNA halogenated adduct and an early biomarker of inflammation-induced oxidative tissue damage. The formation of 8-Bromo-2'-deoxyguanosine precedes that of oxidative and nitrative products, and it can be generated via the MPO-H2O2-Cl--Br- system. 8-Bromo-2'-deoxyguanosine serves as the immunogen for preparing the monoclonal antibody mAb8B3, which can be used to detect early DNA modifications in preclinical models; its urinary level also increases significantly in inflammatory disease models. 8-Bromo-2'-deoxyguanosine can also be produced in the dermis of UV-B irradiated mice, and the extract of Coprinus comatus significantly reduces its level. 8-Bromo-2'-deoxyguanosine finds applications in studies related to inflammatory diseases, diabetes, hepatocellular carcinoma, and UV-B induced skin inflammation.
    8-Bromo-2'-deoxyguanosine-<sup>13</sup>C,<sup>15</sup>N<sub>2</sub>
  • HY-P990809
    Anti-Mouse 4-1BB/CD137 Antibody (LOB12.3) 98.86%
    Anti-Mouse 4-1BB/CD137 Antibody (LOB12.3) is an agonistic mouse-derived IgG2a κ antibody, targeting to mouse 4-1BB/CD137. Anti-Mouse 4-1BB/CD137 Antibody (LOB12.3) can stimulate 4-1BB signaling and induce T cell mediated antitumor immunity. Anti-Mouse 4-1BB/CD137 Antibody (LOB12.3) can be used for the researches of cancer, infection, immunology and neurological disease, such as glioblastoma and retrovirus infection.
    Anti-Mouse 4-1BB/CD137 Antibody (LOB12.3)
  • HY-B1751E
    Quinidine polygalacturonate 27555-34-6
    Quinidine polygalacturonate is an antiarrhythmic agent. Quinidine polygalacturonate is a potent, orally active, selective cytochrome P450db inhibitor. Quinidine polygalacturonate is also a K+ channel blocker with an IC50 of 19.9 μM, and can induce apoptosis. Quinidine polygalacturonate can be used for malaria research.
    Quinidine polygalacturonate
  • HY-178974
    STK10-IN-1
    SLK/STK10-IN-2 (Compound 23) is a highly selective STK10 inhibitor, with a Kd of 365 nM and an IC50 of 0.85 μM. SLK/STK10-IN-2 exhibits EC50 of 0.89 μM in NanoBRET cell experiments. SLK/STK10-IN-2 shows no significant binding to SLK, STK3/4. SLK/STK10-IN-2 can be used to study STK10-related diseases (such as abnormal lymphocyte migration).
    STK10-IN-1
  • HY-163511
    PI3K/Akt/mTOR-IN-4
    PI3K/Akt/mTOR-IN-4 (compound 4r) is a potent PI3K/Akt/mTOR and tubulin polymerization inhibitor. PI3K/Akt/mTOR-IN-4 induce apoptosis and cell cycle arrest at G2/M phase. PI3K/Akt/mTOR-IN-4 decreases the expression of p-PI3K, p-Akt, and p-mTOR, β-tubulin.
    PI3K/Akt/mTOR-IN-4
  • HY-162274
    Oxazepine
    Oxazepine (compound 4a) has antimicrobial viability via binding OMPA/ exo-1,3-beta-glucanase proteins. Oxazepine is a hedgehog signaling inhibitor with antitumor viability.
    Oxazepine
  • HY-183098
    UNC8209
    UNC8209 is a selective PROTAC-based TANK-binding kinase 1 (TBK1) degrader. UNC8209 recruits cereblon (CRBN) to mediate ubiquitin-proteasome pathway-dependent TBK1 degradation and reduces AAK1, GAK, and AURKA abundance. UNC8209 suppresses tumor cell proliferation, impairs in vivo tumor growth, inhibits colony and clonogenic growth and enhances tumor cell sensitivity to TNFα or IFN-γ. UNC8209 modulates cell cycle and induces mild apoptosis. UNC8209 can be used for the research of clear cell renal cell carcinoma, non-small cell lung cancer, pancreatic ductal adenocarcinoma.
    UNC8209
  • HY-144774
    Topoisomerase I inhibitor 5 2513461-95-3
    Topoisomerase I inhibitor 5 is an effective topoisomerase inhibitor with IC50 value of. Topoisomerase I inhibitor 5 can interfere with DNA and significantly inhibit the activity of Topoisomerase I. Topoisomerase I inhibitor 5 can arrest cell cycle at the G1 phase and induce MCF-7 cells apoptosis. Topoisomerase I inhibitor 5 has potency in reversing P-gp-mediated resistance to Adriamycin.
    Topoisomerase I inhibitor 5
  • HY-N0295R
    Protocatechualdehyde (Standard) 139-85-5
    Protocatechualdehyde (Standard) is the analytical standard of Protocatechualdehyde. This product is intended for research and analytical applications. Protocatechualdehyde (Catechaldehyde), a natural polyphenol compound isolated from the roots of radix Salviae Miltiorrhizae, is associated with a wide variety of biological activities and has been widely used in medicine as an antioxidant, anti-aging, an antibacterial and anti-inflammatory agent.
    Protocatechualdehyde (Standard)
  • HY-146395
    HBV-IN-23 2413649-89-3
    HBV-IN-23 (Compound 5k) is an inhibitor of HBV DNA replication with an IC50 of 0.58 μM. HBV-IN-23 inhibits HBV DNA replication in both agent sensitive and resistant HBV strains. HBV-IN-23 shows anti-hepatocellular carcinoma cell (HCC) activities. HBV-IN-23 induces HepG2 cells apoptosis.
    HBV-IN-23
  • HY-B0078B
    Dacarbazine hydrochloride 17925-90-5
    Dacarbazine hydrochloride is a cell cycle nonspecific antineoplastic alkylating agent. Dacarbazine hydrochloride inhibits T and B lymphoblastic response, with IC50 values of 50 and 10 μg/mL, respectively. Dacarbazine hydrochloride can be used for the research of metastatic malignant melanoma.
    Dacarbazine hydrochloride
  • HY-144697
    p38 MAPK-IN-3
    p38 MAPK-IN-3 (Compound 2c) is a p38α MAPK inhibitor. p38 MAPK-IN-3 has antitumor activities and induces apoptosis and ROS.
    p38 MAPK-IN-3
  • HY-181648
    Gal-1-IN-1 3059548-99-8
    Gal-1-IN-1 is a potent and selective human galectin-1 (hGal-1) inhibitor with a Ki of 0.022 μM. Gal-1-IN-1 blocks hGal-1 binding to tumor cells and suppresses human galectin-1-induced pre-apoptosis state. Gal-1-IN-1 reduces hGal-1-expressing cancer cell viability. Gal-1-IN-1 can be used for the research of breast cancer.
    Gal-1-IN-1